skip to the content

Clinical Trials

Acute Lymphoblastic Leukemia - Pediatric Clinical Trial (07.10.043T)

ERWINASE - Erwinia Chrysanthemi L -asparaginase for injection IND 290

Protocol ID

07.10.043T

Protocol Description

Erwinia L-Asparaginase (Erwinase®) for Injection is an investigational new drug being studied to evaluate its effectiveness in the treatment of acute lymphoblastic leukemia (ALL) in patients who are hypersensitive (allergic) to E. coli L-asparaginase or pegasparase (pegylated E. coli L-asparaginase) injections. Erwinase is manufactured in the UK where it is approved by the UK MHRA (Healthcare Authority) and distributed for ALL and lymphoma. Erwinia is not yet approved by the US FDA.

Eligibility Criteria

Children and adolescents with acute lylmphoblastic leukemia

Primary Investigator(s)

  • Arlene Redner, MD

Contact Information

Christine Grabowski, CCRP
(718) 470-3401
grabowsk@lij.edu

Last Update

November 12, 2009
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Children's Health:
top
top